<p>DAVENPORT &amp; Co LLC 在最近向美国证券交易委员会提交的 13F 表格中表示，在第三季度将其在 DexCom, Inc.（NASDAQ:DXCM - 免费报告）的持股增加了 21.5%。该公司在此期间额外购买了 15,024 股后，持有该医疗设备公司 84,967 股股票。DAVENPORT &amp; Co LLC 在 DexCom 的持股在最近一个季度末价值 5,717,000 美元。</p>
<ul>
<li>从分红到增长：为什么这三只股票在 2025 年脱颖而出</li>
</ul>
<p>其他几家机构投资者最近也增加或减少了在 DXCM 的持股。SWS Partners 在第二季度收购了 DexCom 的新股份，价值 1,661,000 美元。Baader Bank Aktiengesellschaft 在第二季度购买了价值约 393,000 美元的 DexCom 新股份。Jennison Associates LLC 在第二季度将其在 DexCom 的持股增加了 9.4%。Jennison Associates LLC 现在持有该医疗设备公司 11,517,546 股股票，价值 1,005,367,000 美元，此前在此期间又购买了 994,300 股。Mn Services Vermogensbeheer B.V. 在第二季度将其在 DexCom 的持股增加了 4.9%。Mn Services Vermogensbeheer B.V. 现在持有该医疗设备公司 146,600 股股票，价值 12,797,000 美元，此前在此期间又购买了 6,800 股。最后，Assenagon Asset Management S.A. 在第二季度将其在 DexCom 的持股增加了 85.7%。Assenagon Asset Management S.A. 现在持有该医疗设备公司 1,208,255 股股票，价值 105,469,000 美元，此前在上个季度又购买了 557,576 股。机构投资者和对冲基金持有该公司 97.75% 的股票。</p>
<h2>DexCom 股价上涨 0.4%</h2>
<p>DXCM 的股票在周五开盘价为 67.15 美元。DexCom, Inc. 的 1 年最低价为 54.11 美元，1 年最高价为 93.25 美元。该公司的债务与股本比率为 0.45，流动比率为 1.56，速动比率为 1.38。该公司的 50 日简单移动平均线为 64.05 美元，200 日简单移动平均线为 73.31 美元。该股票的市值为 261.9 亿美元，市盈率为 37.30，市盈增长比率为 1.45，贝塔值为 1.51。</p>
<ul>
<li>最具性价比？两只上涨潜力超过 30% 的便宜股票</li>
</ul>
<p>DexCom（NASDAQ:DXCM - 获取免费报告）最近于 10 月 30 日星期四发布了季度财报。该医疗设备公司报告本季度每股收益为 0.61 美元，超出分析师一致预期的 0.57 美元，超出幅度为 0.04 美元。DexCom 的股本回报率为 30.65%，净利润率为 15.96%。该公司本季度的收入为 12.1 亿美元，而分析师预期为 11.8 亿美元。在去年同期，该公司每股收益为 0.45 美元。与去年同期相比，该公司的季度收入增长了 21.6%。股票分析师预测 DexCom, Inc. 本财年的每股收益将达到 2.03 美元。</p>
<h2>DexCom 内部活动</h2>
<p>在其他新闻中，首席运营官 Jacob Steven Leach 于 11 月 10 日星期一购买了该公司 18,200 股股票。每股平均购买价格为 55.04 美元，总交易额为 1,001,728.00 美元。交易完成后，首席运营官持有该公司 331,697 股股票，价值 18,256,602.88 美元。此次交易使其持股增加了 5.81%。该交易已在美国证券交易委员会的备案中披露，具体信息可在此链接查看。此外，董事 Bridgette P. Heller 于 11 月 12 日星期三出售了 1,012 股 DexCom 股票。该股票以每股平均价格 58.07 美元出售，总交易额为 58,766.84 美元。交易完成后，该董事直接持有该公司 27,031 股股票，价值 1,569,690.17 美元。此次交易使其持股减少了 3.61%。有关此次出售的更多细节可在官方 SEC 披露中找到。在上个季度，内部人士出售了价值 448,177 美元的 7,866 股公司股票。内部人士持有该股票的 0.32%。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>DexCom 股票：盈利超预期和新市场准入推动看涨预期</li>
</ul>
<p>DXCM 已成为几份研究分析师报告的主题。Oppenheimer 在 9 月 8 日星期一的研究报告中将 DexCom 的评级从 “跑赢大盘” 下调至 “市场表现”。Stifel Nicolaus 于 10 月 21 日星期二开始对 DexCom 的股票进行覆盖。他们给予了 “买入” 评级，并设定了 85.00 美元的目标价。Cowen 在 10 月 24 日星期五的研究报告中重申了对 DexCom 股票的 “买入” 评级。华尔街 Zen 在 11 月 16 日星期日的报告中将 DexCom 的股票评级从 “强力买入” 下调至 “买入”。最后，摩根士丹利在 12 月 2 日星期二将 DexCom 的评级从 “持平” 上调至 “增持”，并将其目标价从 63.00 美元提高至 75.00 美元。三位股票研究分析师对该股票给予了强烈买入评级，十九位给予了买入评级，五位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为 86.61 美元。</p>
<p><strong>获取我们最新的 DXCM 股票分析</strong></p>
<h2>DexCom 公司简介</h2>
<p>（免费报告）</p>
<p>DexCom, Inc. 是一家医疗设备公司，开发、制造和分销用于糖尿病患者的连续血糖监测（CGM）系统。其产品旨在提供近实时的血糖读数、趋势信息和警报，以帮助患者和临床医生管理胰岛素剂量，减少低血糖和高血糖。该公司的产品结合了可穿戴的血糖传感器、无线发射器和软件应用程序，将数据传输到智能手机、专用接收器和基于云的平台进行远程监控。</p>
<p>德康医疗成立于 1999 年，总部位于加利福尼亚州圣地亚哥，专注于推进连续血糖监测（CGM）技术，并扩大其在传统胰岛素依赖人群之外的临床应用。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票比德康医疗更好</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿准备迎战</li>
<li>在 1 月 1 日之前投资 1000 美元于这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
<li>来自奇怪的新 “AI 燃料” 的 33000% 暴涨？</li>
</ul>
<p><strong>想看看其他对 DXCM 感兴趣的对冲基金持有哪些股票？</strong> 访问 HoldingsChannel.com，获取德康医疗（NASDAQ:DXCM - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元于德康医疗吗？</h2>
<p>在考虑德康医疗之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而德康医疗并不在名单上。</p>
<p>虽然德康医疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

德康医疗

<p>根据 DAVENPORT & Co LLC 最近向美国证券交易委员会提交的 13F 表格，第三季度其在 DexCom, Inc.（NASDAQ:DXCM - 免费报告）股票中的持股增加了 21.5%</p>

<p>DAVENPORT &amp; Co LLC lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 21.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 84,967 shares of the medical device company's stock after buying an additional 15,024 shares during the period. DAVENPORT &amp; Co LLC's holdings in DexCom were worth $5,717,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>DAVENPORT &amp; Co LLC 在最近向美国证券交易委员会提交的 13F 表格中表示，在第三季度将其在 DexCom, Inc.（NASDAQ:DXCM - 免费报告）的持股增加了 21.5%。该公司在此期间额外购买了 15,024 股后，持有该医疗设备公司 84,967 股股票。DAVENPORT &amp; Co LLC 在 DexCom 的持股在最近一个季度末价值 5,717,000 美元。</p>
</div><ul>
<li>From Dividends to Growth: Why These 3 Stocks Stand Out in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>从分红到增长：为什么这三只股票在 2025 年脱颖而出</li>
</ul>
</div><p>Several other institutional investors have also recently added to or reduced their stakes in DXCM. SWS Partners acquired a new stake in shares of DexCom in the 2nd quarter worth $1,661,000. Baader Bank Aktiengesellschaft purchased a new stake in DexCom in the 2nd quarter valued at approximately $393,000. Jennison Associates LLC increased its position in DexCom by 9.4% during the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company's stock worth $1,005,367,000 after purchasing an additional 994,300 shares during the period. Mn Services Vermogensbeheer B.V. increased its position in DexCom by 4.9% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company's stock worth $12,797,000 after purchasing an additional 6,800 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in shares of DexCom by 85.7% in the second quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company's stock valued at $105,469,000 after buying an additional 557,576 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者最近也增加或减少了在 DXCM 的持股。SWS Partners 在第二季度收购了 DexCom 的新股份，价值 1,661,000 美元。Baader Bank Aktiengesellschaft 在第二季度购买了价值约 393,000 美元的 DexCom 新股份。Jennison Associates LLC 在第二季度将其在 DexCom 的持股增加了 9.4%。Jennison Associates LLC 现在持有该医疗设备公司 11,517,546 股股票，价值 1,005,367,000 美元，此前在此期间又购买了 994,300 股。Mn Services Vermogensbeheer B.V. 在第二季度将其在 DexCom 的持股增加了 4.9%。Mn Services Vermogensbeheer B.V. 现在持有该医疗设备公司 146,600 股股票，价值 12,797,000 美元，此前在此期间又购买了 6,800 股。最后，Assenagon Asset Management S.A. 在第二季度将其在 DexCom 的持股增加了 85.7%。Assenagon Asset Management S.A. 现在持有该医疗设备公司 1,208,255 股股票，价值 105,469,000 美元，此前在上个季度又购买了 557,576 股。机构投资者和对冲基金持有该公司 97.75% 的股票。</p>
</div><h2>DexCom Trading Up 0.4%</h2>
<div class="lb-trans"><h2>DexCom 股价上涨 0.4%</h2>
</div><p>Shares of DXCM opened at $67.15 on Friday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. The firm has a 50 day simple moving average of $64.05 and a 200-day simple moving average of $73.31. The stock has a market cap of $26.19 billion, a price-to-earnings ratio of 37.30, a price-to-earnings-growth ratio of 1.45 and a beta of 1.51.</p>
<div class="lb-trans"><p>DXCM 的股票在周五开盘价为 67.15 美元。DexCom, Inc. 的 1 年最低价为 54.11 美元，1 年最高价为 93.25 美元。该公司的债务与股本比率为 0.45，流动比率为 1.56，速动比率为 1.38。该公司的 50 日简单移动平均线为 64.05 美元，200 日简单移动平均线为 73.31 美元。该股票的市值为 261.9 亿美元，市盈率为 37.30，市盈增长比率为 1.45，贝塔值为 1.51。</p>
</div><ul>
<li>Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>最具性价比？两只上涨潜力超过 30% 的便宜股票</li>
</ul>
</div><p>DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The company had revenue of $1.21 billion during the quarter, compared to analysts' expectations of $1.18 billion. During the same period in the previous year, the firm posted $0.45 earnings per share. The business's revenue for the quarter was up 21.6% compared to the same quarter last year. Equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>DexCom（NASDAQ:DXCM - 获取免费报告）最近于 10 月 30 日星期四发布了季度财报。该医疗设备公司报告本季度每股收益为 0.61 美元，超出分析师一致预期的 0.57 美元，超出幅度为 0.04 美元。DexCom 的股本回报率为 30.65%，净利润率为 15.96%。该公司本季度的收入为 12.1 亿美元，而分析师预期为 11.8 亿美元。在去年同期，该公司每股收益为 0.45 美元。与去年同期相比，该公司的季度收入增长了 21.6%。股票分析师预测 DexCom, Inc. 本财年的每股收益将达到 2.03 美元。</p>
</div><h2>Insider Activity at DexCom</h2>
<div class="lb-trans"><h2>DexCom 内部活动</h2>
</div><p>In other news, COO Jacob Steven Leach bought 18,200 shares of the firm's stock in a transaction that occurred on Monday, November 10th. The shares were purchased at an average price of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the transaction, the chief operating officer owned 331,697 shares in the company, valued at $18,256,602.88. The trade was a 5.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares of the company's stock, valued at $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 7,866 shares of company stock valued at $448,177. 0.32% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席运营官 Jacob Steven Leach 于 11 月 10 日星期一购买了该公司 18,200 股股票。每股平均购买价格为 55.04 美元，总交易额为 1,001,728.00 美元。交易完成后，首席运营官持有该公司 331,697 股股票，价值 18,256,602.88 美元。此次交易使其持股增加了 5.81%。该交易已在美国证券交易委员会的备案中披露，具体信息可在此链接查看。此外，董事 Bridgette P. Heller 于 11 月 12 日星期三出售了 1,012 股 DexCom 股票。该股票以每股平均价格 58.07 美元出售，总交易额为 58,766.84 美元。交易完成后，该董事直接持有该公司 27,031 股股票，价值 1,569,690.17 美元。此次交易使其持股减少了 3.61%。有关此次出售的更多细节可在官方 SEC 披露中找到。在上个季度，内部人士出售了价值 448,177 美元的 7,866 股公司股票。内部人士持有该股票的 0.32%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>DexCom Stock: Earnings Beat and New Market Access Drive Bull Case</li>
</ul>
<div class="lb-trans"><ul>
<li>DexCom 股票：盈利超预期和新市场准入推动看涨预期</li>
</ul>
</div><p>DXCM has been the subject of several research analyst reports. Oppenheimer cut DexCom from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Monday, September 8th. Stifel Nicolaus began coverage on shares of DexCom in a report on Tuesday, October 21st. They issued a &#34;buy&#34; rating and a $85.00 price target for the company. Cowen reiterated a &#34;buy&#34; rating on shares of DexCom in a research note on Friday, October 24th. Wall Street Zen cut shares of DexCom from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Sunday, November 16th. Finally, Morgan Stanley raised DexCom from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and boosted their price target for the stock from $63.00 to $75.00 in a research note on Tuesday, December 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $86.61.</p>
<div class="lb-trans"><p>DXCM 已成为几份研究分析师报告的主题。Oppenheimer 在 9 月 8 日星期一的研究报告中将 DexCom 的评级从 “跑赢大盘” 下调至 “市场表现”。Stifel Nicolaus 于 10 月 21 日星期二开始对 DexCom 的股票进行覆盖。他们给予了 “买入” 评级，并设定了 85.00 美元的目标价。Cowen 在 10 月 24 日星期五的研究报告中重申了对 DexCom 股票的 “买入” 评级。华尔街 Zen 在 11 月 16 日星期日的报告中将 DexCom 的股票评级从 “强力买入” 下调至 “买入”。最后，摩根士丹利在 12 月 2 日星期二将 DexCom 的评级从 “持平” 上调至 “增持”，并将其目标价从 63.00 美元提高至 75.00 美元。三位股票研究分析师对该股票给予了强烈买入评级，十九位给予了买入评级，五位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为 86.61 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on DXCM</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 DXCM 股票分析</strong></p>
</div><h2>DexCom Company Profile</h2>
<div class="lb-trans"><h2>DexCom 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.</p>
<div class="lb-trans"><p>DexCom, Inc. 是一家医疗设备公司，开发、制造和分销用于糖尿病患者的连续血糖监测（CGM）系统。其产品旨在提供近实时的血糖读数、趋势信息和警报，以帮助患者和临床医生管理胰岛素剂量，减少低血糖和高血糖。该公司的产品结合了可穿戴的血糖传感器、无线发射器和软件应用程序，将数据传输到智能手机、专用接收器和基于云的平台进行远程监控。</p>
</div><p>Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.</p>
<div class="lb-trans"><p>德康医疗成立于 1999 年，总部位于加利福尼亚州圣地亚哥，专注于推进连续血糖监测（CGM）技术，并扩大其在传统胰岛素依赖人群之外的临床应用。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than DexCom</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>The McDonald's Secret</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比德康医疗更好</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿准备迎战</li>
<li>在 1 月 1 日之前投资 1000 美元于这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
<li>来自奇怪的新 “AI 燃料” 的 33000% 暴涨？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding DXCM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 DXCM 感兴趣的对冲基金持有哪些股票？</strong> 访问 HoldingsChannel.com，获取德康医疗（NASDAQ:DXCM - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=DXCM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DexCom Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元于德康医疗吗？</h2>
</div><p>Before you consider DexCom, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑德康医疗之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而德康医疗并不在名单上。</p>
</div><p>While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然德康医疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

DAVENPORT & Co LLC 增加了在 DexCom 公司$DXCM 的持仓